Rajwanth Veluswamy, Associate Professor of Medicine at NYU Langone Health, shared a post on LinkedIn:
“KRAS-targeted therapy is evolving rapidly and so is the way we care for patients!
Over the past few years, we’ve seen remarkable progress in the development of KRAS-targeted therapies across multiple solid tumors. With new data emerging at the 2026 ASCO Annual Meeting, one of the biggest challenges is translating these findings into practical treatment decisions for our patients.
I’m excited to be chairing an upcoming free virtual Oncology Town Hall: From Evidence to Action: Applying KRAS-Targeted Advances in Solid Tumors
July 30, 2026 at 10:30AM
Joining me are two outstanding colleagues:
- Alison Schram (Memorial Sloan Kettering Cancer Center)
- Brian M. Wolpin (Dana-Farber Cancer Institute)
Together, we’ll discuss:
- The most impactful KRAS-related data from ASCO 2026
- How emerging evidence should influence treatment selection
- Practical management of efficacy and toxicity
- Clinical implications across Lung, GI, and Gynecologic cancers
The program is free to attend, and we would be delighted to have you join us. Register here.”
